Puma Biotechnology (PBYI) Stock Price, News & Analysis

Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $4.96 to $5.15
• 50-Day Range: $3.07 to $5.73
• 52-Week Range: $2.22 to $6.07
• Volume: 568,516 shs
• Average Volume: 942,291 shs
• Market Capitalization: $256.89 million
• P/E Ratio: 5.20
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

Puma Biotechnology Stock Analysis - MarketRank™

Puma Biotechnology scored higher than 83% of companies evaluated by MarketBeat, and ranked 196th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Puma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Puma Biotechnology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.58%

Earnings Growth

Earnings for Puma Biotechnology are expected to grow by 22.58% in the coming year, from $0.31 to $0.38 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Puma Biotechnology is 5.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of Puma Biotechnology is 5.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.85.

Price to Book Value per Share Ratio

Puma Biotechnology has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.33% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Puma Biotechnology has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Puma Biotechnology does not currently pay a dividend.

Dividend Growth

Puma Biotechnology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.33% of the float of Puma Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Puma Biotechnology has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Puma Biotechnology has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.78

News Sentiment

Puma Biotechnology has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for PBYI on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $596,914.00 in company stock.

Percentage Held by Insiders

23.30% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBYI Stock Analysis - Frequently Asked Questions

How have PBYI shares performed this year?

Puma Biotechnology's stock was trading at $3.05 at the start of the year. Since then, PBYI shares have increased by 67.2% and is now trading at $5.10.

How were Puma Biotechnology's earnings last quarter?

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, February, 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.29. The biopharmaceutical company had revenue of $59.10 million for the quarter, compared to analysts' expectations of $52.50 million. Puma Biotechnology had a trailing twelve-month return on equity of 53.15% and a net margin of 20.38%.
Read the conference call transcript.

Who are Puma Biotechnology's major shareholders?

Puma Biotechnology's top institutional shareholders include Acorn Capital Advisors LLC (8.20%), American Century Companies Inc. (2.66%), Kennedy Capital Management LLC (1.96%) and Geode Capital Management LLC (1.96%). Insiders that own company stock include Alan H Auerbach, Douglas M Hunt, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Jay M Moyes, Michael Patrick Miller, Alessandra Cesano and Adrian Senderowicz.
View institutional ownership trends.

How do I buy shares of Puma Biotechnology?

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Puma Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), Humana (HUM), American Water Works (AWK) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 2/27/2025
• Today: 8/27/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PBYI
• CIK: 1401667
• Web: www.pumabiotechnology.com
• Phone: (424) 248-6500
• Fax: 424-248-6501
• Employees: 200
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Puma Biotechnology: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +37.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.98
• Trailing P/E Ratio: 5.20
• Forward P/E Ratio: 16.45
• P/E Growth: N/A
• Net Income: $30.28 million
• Net Margins: 20.38%
• Pretax Margin: 17.76%
• Return on Equity: 53.15%
• Return on Assets: 23.51%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 1.73
• Quick Ratio: 1.62

Sales & Book Value

• Annual Sales: $230.50 million
• Price / Sales: 1.11
• Cash Flow: $0.84 per share
• Price / Cash Flow: 6.08
• Book Value: $2.08 per share
• Price / Book: 2.45

Miscellaneous

• Outstanding Shares: 50,370,000
• Free Float: 38,635,000
• Market Cap: $256.89 million
• Optionable: Optionable
• Beta: 1.30